| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| γ-Linolenic acid (GLA) — an omega-6 polyunsaturated fatty acid (18:3 n-6) found in high concentration in borage oil, evening primrose oil, and blackcurrant seed oil. Metabolized to dihomo-γ-linolenic acid (DGLA) → precursor of anti-inflammatory eicosanoids (e.g., PGE1). Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Orally absorbed and incorporated into membrane phospholipids; rapidly elongated to DGLA. Plasma levels achievable with supplementation; cellular effects reflect incorporation over days–weeks (remodeling). In-vitro vs oral exposure: Direct tumor cytotoxicity generally observed at supra-physiologic concentrations; physiologic doses mainly alter lipid signaling rather than induce apoptosis. Clinical evidence status: Used for inflammatory conditions (e.g., dermatitis, RA); oncology data limited and inconsistent; no cancer approval. GLA (abundant in borage oil) has shown anti-proliferative and pro-apoptotic effects on multiple cancer cell lines and in animal models (mechanisms include ER stress, mitochondrial dysfunction, altered eicosanoid signaling).-Borage plants can contain unsaturated PAs(Pyrrolizidine alkaloids) which are hepatotoxic and genotoxic/carcinogenic. Many authorities advise only using borage oil products certified PA-free, and caution against long-term or high-dose use. -γ-gamma linolenic acid (GLA, 18:3n-6) are polyunsaturated fatty acids (PUFA) that improve the human health γ-Linolenic Acid (Borage Oil) — Cancer vs Normal Cell Pathway Map
TSF legend: |
| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 4505- | GLA, | Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α |
| - | in-vitro, | NSCLC, | Calu-1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:374 Target#:324 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid